Aldehyde dehydrogenase-expressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer.
Patients with chronic ulcerative colitis are at increased risk of developing colorectal cancer. Although current hypotheses suggest that sporadic colorectal cancer is due to inability to control cancer stem cells, the cancer stem cell hypothesis has not yet been validated in colitis-associated cancer. Furthermore, the identification of the colitis to cancer transition is challenging. We recently showed that epithelial cells with the increased expression of aldehyde dehydrogenase in sporadic colon cancer correlate closely with tumor-initiating ability. We sought to determine whether ALDH can be used as a marker to isolate tumor-initiating populations from patients with chronic ulcerative colitis. We used fluorescence-activated cell sorting to identify precursor colon cancer stem cells from colitis patients and report both their transition to cancerous stem cells in xenografting studies as well as their ability to generate spheres in vitro. Similar to sporadic colon cancer, these colitis-derived tumors were capable of propagation as sphere cultures. However, unlike the origins of sporadic colon cancer, the primary colitic tissues did not express any histologic evidence of dysplasia. To elucidate a potential mechanism for our findings, we compared the stroma of these different environments and determined that at least one paracrine factor is up-regulated in the inflammatory and malignant stroma compared with resting, normal stroma. These data link colitis and cancer identifying potential tumor-initiating cells from colitic patients, suggesting that sphere and/or xenograft formation will be useful to survey colitic patients at risk of developing cancer.
Carpentino
Joseph E
JE
McKnight Brain Institute, University of Florida, Gainesville, Florida 32609, USA.
Hynes
Mark J
MJ
Appelman
Henry D
HD
Zheng
Tong
T
Steindler
Dennis A
DA
Scott
Edward W
EW
Huang
Emina H
EH
D000230:Adenocarcinoma / Q000201:enzymology / Q000209:etiology / Q000473:pathology; D000444:Aldehyde Dehydrogenase / Q000378:metabolism*; D000818:Animals; D003092:Colitis / Q000201:enzymology / Q000473:pathology*; D003106:Colon / Q000201:enzymology / Q000473:pathology; D003110:Colonic Neoplasms / Q000201:enzymology / Q000209:etiology* / Q000473:pathology*; D016207:Cytokines / Q000378:metabolism; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D006801:Humans; D007124:Immunoenzyme Techniques; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D014411:Neoplastic Stem Cells / Q000201:enzymology* / Q000473:pathology; D011230:Precancerous Conditions / Q000201:enzymology / Q000209:etiology / Q000473:pathology; D040081:Protein Array Analysis; D018874:Spheroids, Cellular / Q000201:enzymology / Q000473:pathology; D017154:Stromal Cells / Q000201:enzymology / Q000473:pathology; D023041:Xenograft Model Antitumor Assays
D016207:Cytokines; D000444:Aldehyde Dehydrogenase